drugset / Trial / NCT02849704
Fat Malabsorption in Chronic Pancreatitis
Phase 2
Completed
48 enrolled
Children's Hospital of Philadelphia
AbbVie · collabNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collabPhoenix Indian Medical Center · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
The objective of this study is to evaluate the malabsorption blood test (MBT), stool coefficient of fat absorption (CFA) and stool bomb calorimetry (BC) methods as potential screening or diagnostic tests for reduced exocrine pancreatic function or pancreatic insufficiency (RPF/PI). A further objective is to determine the test responses before and after pancreatic enzyme medication administration (Creon36™) in the patients with chronic pancreatitis (CP).
Timeline
- Start
- 2016-10-13
- Primary completion
- 2017-11-01
- Completion
- 2017-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pancrelipase | Protein / enzyme biologic | 36000 iu | — |
| Subject | Pancrelipase | Protein / enzyme biologic | 72000 iu | — |